Procedural propofol sedation with ketamine versus alfentanil and remifentanil in patients for cardiac ablation.

• Conditions: We designed this study to compare the effects of propofol-ketamine versus propofol-alfentanil and propofol-remifentanil for achieving a more acceptable respiratory stability with a decrease in respiratory side effects during PSA for CA treatment.

• Registration Number: NL-OMON28894
• Lead Sponsor: Catharina Hospital EindhovenMichelangelolaan 25623 EJ EindhovenThe Netherlands040-2399111www.cze.nl

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

Patients were eligible if are: scheduled for treatment of atrial fibrillation with CA under PSA, aged 18 years or older, American Society of Anesthesiology (ASA) class 1 to 3.

Patients will be included in this study after given written informed consent before the treatment starts.

Exclusion Criteria

Patients will be excluded from the study if they: are unable to give informed consent, are pregnant, have a known allergy to either study medication, have a know contra-indication to administer either study medication, are scheduled for a repeated procedure, are receiving treatment for neuromuscular or psychiatric disease and have a physical or communicational disorder.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint of this study is respiratory stability with the applied sedational technique. Differences in respiration rate, number of apneas and oxygen saturation with the applied inspiratory fraction of oxygen, combined with the administered doses of PSA medication, between the three study groups will be compared.